Clinical trials: Immune-related Vitiligo-like-Depigmentation
Immune-related Vitiligo-like-Depigmentation
Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation
White spot disease is a common side effect on the skin in the context of cancer treatments with immunotherapies. There is no standard therapy yet for white spot caused by cancer therapies.
- Trial name
- TRuE-VLD (NCT07725432)
- Testing
- Ruxolitinib Topical Cream
- Where
- Switzerland
- Volunteers
- 34 people
- Sponsor
- University of Zurich